Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Oct 21,2022
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Shanghai Medicilon Inc. was awarded the honorary title of "Top 30 Listed Companies on the Science and Technology Innovation Board".
More
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Oct 19,2022
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of CMC.
More
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Sep 29,2022
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.
More
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Sep 29,2022
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.
More
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
Sep 26,2022
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park. This is another grand event following the opening of Medicilon (Hangzhou) on September 7.
More
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
Sep 14,2022
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.
More
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
Sep 14,2022
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.
More
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
Sep 01,2022
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.
More
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Aug 29,2022
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.
More
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
Aug 15,2022
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Recently, the SMDC released the list of the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022". With its strong scientific and technological innovation strength, Shanghai Medicilon Inc. stands out from many outstanding enterprises and ranks among the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022".
More
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Aug 15,2022
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"
On August 4, 2022, the 6th China Bio-Pharma Partnering Forum 2022 and the 2022 China Biomedical Industry Value List Award Ceremony was held, Shanghai Medicilon Inc. was on the list of the "Top 20 Most Influential CXO Enterprise."
More
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"